Home/Hedge Fund Intelligence/Sofinnova Bioequities Master Fund
Hedge FundCayman IslandsMaster fund3(c)(7) · qualified purchasers

Sofinnova Bioequities Master Fund

Estimated returns, assets and SEC record

Managed by Sofinnova Investments, Inc. · Menlo Park · in Form ADV since 2017

Sofinnova Bioequities Master Fund is a Cayman Islands hedge fund managed by Sofinnova Investments, Inc. It reported gross assets of USD 204m in the Form ADV filed 27 September 2024. Hedge funds do not file their returns with the SEC. From what this fund and its manager do file, PPLI Vortex estimates that it returned about 40.1% in 2025, with a likely range of 14.7% to 65.4%.

Unqualified audit opinionIndependent administratorPCAOB-registered auditor
2025, estimated+40.1%range 14.7% to 65.4% · grade D-13F · estimated for the manager as a whole
Three years, a year+25.4%2023 to 2025, compounded from the yearly estimates and their ranges
Latest quarter+5.1%to 30 Jun 2026 · range -5.2% to 21.9%
Gross assetsUSD 204mForm ADV · filed 27 Sep 2024
Minimum investmentUSD 3mForm ADV, Schedule D
Investors50beneficial owners

Compiled by PPLI Vortex from SEC filings · Hedge Fund Intelligence, PPLI.com · updated · about PPLI Vortex

Return figures are PPLI.com estimates from public SEC filings, not numbers reported by the fund. Not investment advice. Important information

PPLI.com
Hedge Fund Rating
Rating in preparation
We publish a rating only once a fund's file has been through editorial review. This fund is in the queue.
Returns
Risk
SEC record and governance
Fees and terms
Fit for a PPLI policy
Editorial assessment from SEC filings
Reviewed every quarter
About the rating
D
Confidence grade D-13F

We rebuild the manager's long positions from Form 13F and scale them to how hedge funds of this kind have behaved. Shorts, leverage and fees are not visible.

How the grades work

A and B are computed from public filings. C, C-est and D-est are estimates built on what registered funds that hold the fund report. D-13F is an estimate from the manager's 13F long book. Every figure on this page is shown with its range and grade.

Quarter by quarter

Sofinnova Bioequities Master Fund, one quarter at a time

How the estimate moved through each year since 2021, with the yearly figure alongside.

Each cell is our estimate for that quarter, with the range it could fall in underneath. The last column is the figure for the full year. It is worked out on its own from the year's filings, so the four quarters will not multiply out to it exactly. Every figure here is graded D-13F and D-est.

YearJan to MarApr to JunJul to SepOct to DecFull year
2026+4.3%-7.4% to 15.9%+5.1%-5.2% to 21.9%not yet filednot yet filed+14.9%-8.3% to 38.2%, to 30 Jun
2025−3.2%-14.9% to 8.4%+6.1%-5.5% to 17.8%+10.8%-0.9% to 22.4%+19.8%8.1% to 31.4%+40.1%14.7% to 65.4%
2024+14.1%1.5% to 26.6%−2.4%-14.0% to 9.2%+4.8%-6.8% to 16.5%−1.2%-12.8% to 10.5%+17.7%-6.4% to 41.9%
2023+0.8%-10.8% to 12.5%+7.4%-4.3% to 19.0%−4.7%-16.3% to 7.0%+22.7%11.0% to 34.3%+19.5%-3.9% to 42.9%
2022−7.3%-18.9% to 4.4%−3.1%-14.8% to 8.5%+16.7%5.0% to 28.3%+0.2%-11.5% to 11.8%+3.6%-19.7% to 26.9%
2021+0.8%-10.8% to 12.5%+0.8%-10.8% to 12.5%+1.6%-10.0% to 13.2%−1.9%-13.6% to 9.7%−0.6%-23.9% to 22.6%

Estimates by PPLI Vortex from public SEC filings, not figures reported by the fund. n/a means the filings do not support a figure for that quarter.

Next: what the manager holds
Holdings

57 positions, with 58% of the money in the ten largest

Sofinnova Bioequities Master Fund does not publish what it owns. Its manager does: every quarter Sofinnova Investments, Inc. lists its U.S.-listed stocks and options on Form 13F. The list covers every account the firm runs, not this fund alone, and leaves out short positions, bonds, swaps and shares listed outside the United States. The book is larger than the firm's hedge funds because it includes other clients, so much of it may not belong to this fund.

Value reportedUSD 1.9bn
Positions57
In the ten largest58%
Largest positionNatera, Inc., 21.8%
Call options, underlying valueUSD 3
Put options, underlying valueUSD 1
Holdings as of30 June 2026
The 15 largest positions

Share is of the total value reported. Options are shown at the value of the shares they cover. Choose a company to see which other managers report it.

#CompanyValueShare of the book
1 Nasdaq: NTRAHeld by 61 of the 720 managers we trackUSD 421m21.8%
2 Nasdaq: VERAClass AHeld by 38 of the 720 managers we trackUSD 120m6.2%
3 Nasdaq: GMABADSHeld by 20 of the 720 managers we trackUSD 111m5.7%
4 Nasdaq: JAZZUsdHeld by 31 of the 720 managers we trackUSD 88m4.6%
5 Nasdaq: RAPPHeld by 18 of the 720 managers we trackUSD 79m4.1%
6 Nasdaq: SPTXHeld by 12 of the 720 managers we trackUSD 77m4.0%
7 Nasdaq: AVBPHeld by 20 of the 720 managers we trackUSD 59m3.0%
8 Nasdaq: RAREHeld by 35 of the 720 managers we trackUSD 57m3.0%
9 Nasdaq: BIOAHeld by 26 of the 720 managers we trackUSD 56m2.9%
10 NYSE: BMYHeld by 58 of the 720 managers we trackUSD 51m2.6%
11 Nasdaq: SUPNHeld by 24 of the 720 managers we trackUSD 48m2.5%
12 Nasdaq: RYTMHeld by 38 of the 720 managers we trackUSD 45m2.3%
13 Nasdaq: GILDHeld by 61 of the 720 managers we trackUSD 43m2.2%
14 Nasdaq: UTHRHeld by 57 of the 720 managers we trackUSD 41m2.1%
15 Nasdaq: COGTHeld by 57 of the 720 managers we trackUSD 40m2.1%
Natera, Inc.: 21.8%Vera Therapeutics, Inc.: 6.2%Genmab A/S: 5.7%Jazz Pharmaceuticals plc: 4.6%Rapport Therapeutics, Inc.: 4.1%Seaport Therapeutics, Inc.: 4.0%ArriVent BioPharma, Inc.: 3.0%Ultragenyx Pharmaceutical Inc.: 3.0%Positions 9 to 15: 16.8%The rest of the book: 30.8%57POSITIONS
How the book is split
  • Natera, Inc.21.8%
  • Vera Therapeutics, Inc.6.2%
  • Genmab A/S5.7%
  • Jazz Pharmaceuticals plc4.6%
  • Rapport Therapeutics, Inc.4.1%
  • Seaport Therapeutics, Inc.4.0%
  • ArriVent BioPharma, Inc.3.0%
  • Ultragenyx Pharmaceutical Inc.3.0%
  • Positions 9 to 1516.8%
  • The rest of the book30.8%
Next: returns year by year
Returns year by year

About 40% in 2025, with a range too wide to call against the index

The SEC filings of Sofinnova Bioequities Master Fund carry no return figures. These are our estimates, each with the range we think the true figure falls in and a grade for how it was reached.

Gold bars are the fund. The thin line on each bar is the range we think the true figure falls in. Grey bars are the S&P 500 total return in U.S. dollars, dividends reinvested, over the same calendar years. It is there as a picture of the market, not as the benchmark this fund sets itself.

-20%0%20%40%60%2021-0.6%20223.6%202319.5%202417.7%202540.1%2026 to date14.9%
PeriodReturnLikely rangeGradeS&P 500Difference
2021-0.6%-23.9% to 22.6%D-13F28.7%-29.4 pts
20223.6%-19.7% to 26.9%D-13F-18.1%+21.7 pts
202319.5%-3.9% to 42.9%D-13F26.3%-6.8 pts
202417.7%-6.4% to 41.9%D-13F25.0%-7.3 pts
202540.1%14.7% to 65.4%D-13F17.9%+22.2 pts
2026 to 30 Jun14.9%-8.3% to 38.2%D-13F

The estimate is built from the manager's whole 13F long book. We attach it to this fund as the largest hedge fund Sofinnova Investments, Inc. runs.

Returns are before the fees an investor pays unless they come from a public holder's reported value, which is after the fund's own fees.

USD 100 in Sofinnova Bioequities Master Fund against the S&P 500start of 2021 = 100

The gold line compounds our yearly figures. The shaded area is where the line would run if every year came in at the low or the high end of its range. The grey line is the S&P 500 with dividends.

100200300400500StartEnd 2021End 2022End 2023End 2024End 2025Fund 203S&P 500 196

By the end of 2025, USD 100 in the fund had become about USD 203 by our estimate, against USD 196 in the index.

What an investor would have kept, 2021 to 2025

Takes our yearly figures for Sofinnova Bioequities Master Fund and shows what is left after fees and tax, next to the same money inside a PPLI policy. Change any of the numbers. Our 13F-based figures price the manager's long book and take no fees off, so the tool treats them as before fees. Public filings do not settle that, and they do not give the fund's terms either. The fees are yours to set; put both at 0 to read the estimate as if it were already after fees.

Sofinnova Bioequities Master Fund, as estimatedour yearly figures compounded, before fees and taxUSD 2m
After the fund's feeswith the fees you entered, charged above a high-water markUSD 1.7m
After tax, held directlygains taxed every year at the rate you enteredUSD 1.4m
Held inside a PPLI policyno yearly tax on gains inside a policy that keeps to the rules, less the yearly policy costUSD 1.6m
S&P 500 with dividendsthe index over the same years, before taxUSD 2m
Each year: as estimated, after fees, after tax and inside a policy
YearAs estimatedAfter feesAfter taxInside a policyS&P 500
2021-0.6%-2.1%-2.1%-3.1%28.7%
20223.6%2.1%2.1%1.1%-18.1%
202319.5%14.4%8.6%13.2%26.3%
202417.7%13.0%7.7%11.9%25.0%
202540.1%30.8%18.3%29.5%17.9%

The fee defaults of 1.5% and 20% are common hedge fund terms, not this fund's. The tax rate of 40.8% is the top U.S. federal rate on short-term gains with the net investment income tax; a fund whose gains are mostly long-term would be taxed at 23.8%. State tax is not included. Policy costs differ by carrier and by the size of the policy. If every year had come in at the bottom or the top of our range, the first line would read USD 630,000 or USD 5.2m. An illustration, not advice.

The record in numbers

Worked out from the yearly figures above, 2021 to 2025. They carry the same ranges and grades.

Annualised return15.2%
Best year40.1% in 2025
Worst year-0.6% in 2021
Years ahead of the S&P 5002 of 5
Total over the period102.8%
S&P 500 over the period96.2%
Losing years1 of 5
Average width of our range48 points
Returns by period

Annualised where the period is longer than a year. The range compounds the low and high ends of each year.

PeriodSofinnova Bioequities Master FundLikely rangeS&P 500Difference
Latest year202540.1%14.7% to 65.4%17.9%+22.2 pts
Three years, a year2023 to 202525.4%1.0% to 49.7%23.0%+2.4 pts
Five years, a year2021 to 202515.2%-8.8% to 39.2%14.4%+0.8 pts
Risk, as far as yearly figures show it

Measured at year ends only. A fall and recovery inside a single year does not appear here.

Deepest fall between year ends-0.6%
Reached at the end of2021
S&P 500, same measure-18.1%
Losing years1 of 5
2022, side by side
Sofinnova Bioequities Master Fund3.6%range -19.7% to 26.9%
S&P 500-18.1%with dividends

2022 was the one year in this period when the index fell. By our estimate the fund made money.

Compare with other funds

Type the name of any fund we estimate and it joins the table. Up to five at a time. Every figure is an estimate; open a fund to see its range and grade.

Fund20212022202320242025
Sofinnova Bioequities Master Fund-0.6%3.6%19.5%17.7%40.1%
S&P 500 with dividends28.7%-18.1%26.3%25.0%17.9%

Over 2023 to 2025 the estimates compound to 97.0%, or 25.4% a year.

Next: where the numbers come from
Where the numbers come from

Built from the manager's quarterly 13F filings

A hedge fund reports almost nothing about itself. Others report about it, and that is what we read.

Registered funds that hold Sofinnova Bioequities Master Fund

Mutual funds and interval funds report every holding to the SEC on Form N-PORT. When one of them owns a stake in a hedge fund, its filings show what that stake was worth on each date.

HolderListed asReportsSeenLatest value held
First Trust Alternative Opportunities FundSOFINNOVA BIOEQUITIES231 Mar 2026 to 30 Jun 2026USD 11m
Sofinnova Investments, Inc.'s disclosed U.S. long book

Every quarter the manager lists its U.S. listed long positions on Form 13F, most recently USD 1.9bn with options counted at the value of the shares they cover for 30 June 2026. Pricing those positions through each year gives the return of the long book alone. It covers all the manager's clients, not this fund, and leaves out shorts, leverage, non-U.S. holdings and fees. The long book is larger than the manager's hedge funds, because it includes other clients. It is a weak guide to this fund.

20212022202320242025
13F long book-13.6%-9.8%32.3%11.5%54.6%
S&P 50028.7%-18.1%26.3%25.0%17.9%
-20%0%20%40%60%20212022202320242025
Next: size and investors
Size and investors

USD 204m in gross assets, down from USD 788m reported in 2022

The fund in Form ADV, Schedule D

What the adviser reported about this fund in the filing of 27 September 2024. Gross assets are the fund's total assets before borrowings are deducted. They are not net assets and say nothing about performance.

Gross asset valueUSD 204m
Minimum investmentUSD 3m
Beneficial owners50
Owned by the adviser and its people29%
Owned by funds of funds16%
Owned by non-U.S. persons11%
Investor eligibility3(c)(7): qualified purchasers
DomicileCayman Islands
StructureMaster fund
Full legal nameSofinnova Bioequities Master Fund, Ltd.
SEC private fund ID805-6556194744
Gross assets over timeUSD m, by the year the figure was filed

Each bar is the gross asset value in that year's Form ADV. An annual filing reports the previous fiscal year end, so each bar describes the year before. A change in gross assets is not a return: money coming in, money going out, borrowing and performance all move it, and the filings do not say which.

201841.5201910220203262021609202278820232132024204
Master and feeder funds

Investors often enter through a feeder that passes their money to a master fund, where the trading happens.

  • Feeder: Sofinnova Bioequities Offshore Fund Ltd.
  • Feeder: Sofinnova Bioequities, LP
Next: who audits and administers it
Service providers

Audited by KPMG, LLP, administered by Citco Fund Administration (Cayman Islands)

An outside auditor and an administrator that is not part of the manager are the two checks an investor can verify from public filings.

Named by the adviser in Form ADV Schedule D, questions 23 to 28, in the filing of 27 September 2024.

RoleFirmWhereAs stated in the filing
AuditorKPMG, LLPSan Francisco, CaliforniaIndependent, pcaob registered
AdministratorCitco Fund Administration (Cayman Islands) LimitedGrand Cayman, Cayman IslandsNot related to the adviser
Prime brokerJefferies LLCSan Francisco, CaliforniaAlso custodian
Prime brokerJ.P. Morgan Securities Inc.San Francisco, CaliforniaAlso custodian
Prime brokerGoldman Sachs & Co. LLCSan Francisco, CaliforniaAlso custodian
CustodianGoldman Sachs InternationalLondon, United KingdomNot related to the adviser
CustodianGoldman Sachs & Co. LLCSan Francisco, CaliforniaNot related to the adviser
CustodianBNY Mellon Trust Company (Ireland) LimitedDublin, IrelandNot related to the adviser
CustodianCitco Bank CanadaToronto, CanadaNot related to the adviser
CustodianJ.P. Morgan Securities LLCNew York, New YorkNot related to the adviser
CustodianJefferies LLCNew York, New YorkNot related to the adviser
Audit and valuation
Audited every yearYes
Statements under U.S. GAAPYes
Audited statements sent to investorsYes
Share of assets valued by an outside party100%
General partner, manager or directors

Form ADV Schedule D, question 3.

  • Sofinnova Bioequities GP L.L.C.
Next: how the fund is offered
The offering, from Form D

Offering filed by a related vehicle

The Form D linked to this fund was filed by Sofinnova BioEquities, LP, a related vehicle of the same manager, often the feeder or offshore twin through which investors come in. The figures below describe that vehicle.

Issuer on the filingSofinnova BioEquities, LP
Total sold to dateUSD 377m
Investors to date77
Date of first sale3 January 2017
Exemptions claimed06b, 3C, 3C.7
EntityLimited Partnership
JurisdictionDelaware
Latest filingD/A, 8 May 2026
Form D filings on EDGAR10
Next: the manager
The manager

Run by Sofinnova Investments

AdviserSofinnova Investments, Inc.
StatusSEC-registered adviser
Registered since22 March 2017
SEC number801-110134
CRD number160297
OfficeMenlo Park, CA
Latest Form ADV27 March 2026
Brochure (Part 2A)27 March 2026
In the manager's own words

What Sofinnova Investments, Inc. says about itself on sofinnova.com, read on 14 November 2026. A sentence in quotation marks is the firm's own; the rest is in our words. These are the firm's statements, not ours, and we have not checked them. They describe the firm as a whole, not this fund.

“Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed .”

What it says it doesHealthcare and biotechnology
Offices it listsNew York, Boston, Menlo Park
People namedNathalie Auber, Partner, CFO
Aneal Tenjarla, Partner
Hooman Shahlavi, Partner, Chief Legal Officer
James Brody, Chief Compliance Officer
Maha Katabi, General Partner
Telephone(650) 681-8420
LinkedInCompany page
On the siteA team page and an investor login
The manager at a glance

Gross assets are added across the funds we cover and count a master fund and its feeders separately, so they overstate the money the firm runs.

Funds of this manager on PPLI.com1
Their gross assets togetherUSD 204m
With return figures1
U.S. long book on Form 13FUSD 1.9bn
Positions in that book57
Form ADV filings that list this fund20
The paper trail

Dates taken from the filings themselves.

  • 3 Mar 2017 First Form ADV in the SEC's bulk data to list the fund
  • 22 Mar 2017 Sofinnova Investments, Inc. registered with the SEC
  • 27 Sep 2024 Latest Form ADV listing the fund in the bulk data
  • 27 Mar 2026 Latest Form ADV of the manager
  • 31 Mar 2026 First appears as a holding of a registered fund
  • 8 May 2026 Latest Form D of the related vehicle
  • 14 Aug 2026 Latest Form 13F of the manager, for 30 June 2026
Next: holding it inside a policy
Inside a policy

Can Sofinnova Bioequities Master Fund be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. U.S. tax rules test what a policy holds for diversification, and a fund that is also sold to investors outside insurance accounts counts as a single holding and is not looked through to what it owns. Choosing such a fund yourself also raises the investor-control question the IRS has ruled on.

In practice a U.S.-compliant policy reaches a hedge fund strategy through an insurance-dedicated fund, whose interests are held by insurers' separate accounts with a few exceptions the regulations allow, or through a separately managed account run for the insurer. Policies issued outside the United States for people who are not U.S. taxpayers follow the rules of their own jurisdiction, and those differ.

Some managers run an insurance-dedicated version of their strategy. Where they do, gains that a taxable investor would pay tax on each year can build up inside the policy, as long as the policy keeps to the rules. We have no record that Sofinnova Investments, Inc. offers one. That is a gap in our file, not a finding that it does not. We keep a directory of insurance-dedicated funds and the managers behind them.

Insurance-dedicated funds on PPLI.com   Hedge fund strategies inside PPLI

The diversification test, on the manager's reported book

The investments inside a policy must be spread: no more than 55% in one holding, 70% in two, 80% in three and 90% in four. This table runs that test on the positions Sofinnova Investments, Inc. reported on Form 13F for 30 June 2026. It is a rough guide only, since an insurance-dedicated version would hold the whole strategy, shorts included.

MeasureLimitThis bookResult
The largest holding55%22%Within the limit
The two largest70%28%Within the limit
The three largest80%34%Within the limit
The four largest90%38%Within the limit

On this evidence the long book is spread widely enough.

Next: notes on this file
Notes

What the filings leave open

What we would ask the manager

Questions the filings raise and cannot answer.

  • You and your people own 29% of the fund. What would it mean for outside investors if you took that money out?
  • Reported gross assets have fallen from USD 788m to USD 204m. How much of that was performance and how much was investors leaving?
  • Our estimate rests on your long book alone. What did the short book, leverage and trading inside the quarter add or take away?
  • Do you offer this strategy as an insurance-dedicated fund or a separately managed account for insurers?
Changes to this file
  • 13 Nov 2026 File opened from SEC filings
  • 14 Nov 2026 Manager's website read and its facts added
  • 15 Nov 2026 Page revised.
The manager's response

Not yet received. Sofinnova Investments, Inc. can ask us to check any fact on this page and can send a response, which we will publish here unedited. Write to the editor.

Next: questions
Questions

Questions about Sofinnova Bioequities Master Fund

What has Sofinnova Bioequities Master Fund returned?

The SEC filings of Sofinnova Bioequities Master Fund carry no return figures. PPLI Vortex estimates, from SEC filings: 19.5% in 2023, 17.7% in 2024, 40.1% in 2025, 14.9% in 2026 to 30 Jun. Each estimate has a range; for 2025 it is 14.7% to 65.4%.

How reliable are the return figures for Sofinnova Bioequities Master Fund?

They are estimates, not figures reported by the fund. Each one is shown with a range and a grade. The grade for the latest figure is D-13F: estimated from the manager's Form 13F long book. Shorts, leverage, trading within a quarter and fees are not visible in public filings.

What does Sofinnova Bioequities Master Fund invest in?

Sofinnova Bioequities Master Fund does not publish its holdings. Its manager, Sofinnova Investments, Inc., reported 57 U.S.-listed positions worth USD 1.9bn on Form 13F for 30 June 2026. The largest were Natera, Inc., Vera Therapeutics, Inc., Genmab A/S. The filing covers all of the manager's accounts and excludes short positions.

How big is Sofinnova Bioequities Master Fund?

Sofinnova Bioequities Master Fund reported gross assets of USD 204m in the Form ADV filed 27 September 2024. Gross assets are total assets before borrowings are deducted, so the figure is larger than what investors have put in when the fund uses leverage.

What is the minimum investment in Sofinnova Bioequities Master Fund?

USD 3m, as stated in Form ADV Schedule D. The fund relies on the 3(c)(7) exclusion, so investors must be qualified purchasers. Managers can and do waive minimums.

Who audits and administers Sofinnova Bioequities Master Fund?

The auditor is KPMG, LLP. The administrator is Citco Fund Administration (Cayman Islands) Limited. These are the firms named in the Form ADV filed 27 September 2024.

Who runs Sofinnova Investments, Inc.?

On its own website Sofinnova Investments, Inc. names Nathalie Auber (Partner, CFO), Aneal Tenjarla (Partner), Hooman Shahlavi (Partner, Chief Legal Officer) and James Brody (Chief Compliance Officer). That is the list the firm gave when we read the site on 14 November 2026, and people move, so check with the firm.

What does Sofinnova Investments, Inc. invest in?

On its website the firm writes mainly about healthcare and biotechnology. That is how it describes itself, and it covers the whole firm, not Sofinnova Bioequities Master Fund alone.

How do I contact Sofinnova Investments, Inc.?

The firm can be reached by email at [email protected] or by telephone on (650) 681-8420, the details it gives on sofinnova.com. PPLI.com is not connected to the firm and cannot pass messages on.

Where is Sofinnova Investments, Inc. based?

Its website lists New York, Boston, Menlo Park. The address on its SEC filing is in the manager section above.

Who manages Sofinnova Bioequities Master Fund?

Sofinnova Investments, Inc., CRD number 160297. It is an SEC-registered adviser.

Can Sofinnova Bioequities Master Fund be held inside a PPLI policy?

Not directly, for a U.S. taxpayer. Under U.S. tax rules a policy reaches a hedge fund strategy through an insurance-dedicated fund or a separately managed account run for the insurer, not through a fund that is also sold to other investors. Policies issued outside the United States follow their own rules. We have no record that Sofinnova Investments, Inc. offers an insurance-dedicated version, so an investor would need to ask the firm.

What did Sofinnova Bioequities Master Fund return each quarter?

Sofinnova Bioequities Master Fund does not file quarterly returns with the SEC. PPLI Vortex estimates 10.8% in the third quarter of 2025, 19.8% in the fourth quarter of 2025, 4.3% in the first quarter of 2026 and 5.1% in the second quarter of 2026. Each figure has a range, shown on the page.

Next: how we work
Method and sources

How this page was put together

The return figures on this page come from PPLI Vortex, the engine we built to work out hedge fund returns from SEC filings. For this fund it takes the long positions the manager reports each quarter on Form 13F, prices them through the following quarter, and scales the result to how hedge funds with a similar footprint have behaved, using publicly reported returns as calibration. It is not the return the fund reports to its investors, which also reflects shorts, derivatives, cash, trading within the quarter and fees. Fund facts come from Form ADV Schedule D, section 7.B.(1), and from Form D. Apart from the short passage taken from the manager's public website and marked as such, nothing here comes from the fund or its manager.

Form ADV usedFiled 27 September 2024
Form D used8 May 2026
Public holder reports to30 June 2026
13F quarter30 June 2026
EnginePPLI Vortex v12.4
CorrectionsWrite to the editor

The full methodology

For the fund and its manager

Do you run Sofinnova Bioequities Master Fund? Help us get it right.

If you manage this fund or work for Sofinnova Investments, Inc., you can correct a fact, send us figures we do not have, such as audited returns, fees and terms, or point out a mistake. So can anyone else who spots one.

[email protected]

Please give the fund's name and its SEC private fund ID, 805-6556194744. We check what we receive against the filings, mark on the page what came from the manager, and publish any response you send, unedited.

Important information

Return figures on this page are estimates computed by PPLI.com from public regulatory filings using its PPLI Vortex engine. They are not reported, confirmed or audited by the fund, each is shown with a range and a confidence grade, and the true figures may differ materially from what investors received.

PPLI.com has no relationship with Sofinnova Bioequities Master Fund or Sofinnova Investments, Inc., and neither has reviewed or approved this page. Facts are taken from filings with the U.S. Securities and Exchange Commission as of the dates shown and may since have changed. Holdings come from the manager's Form 13F, which covers all of its accounts and omits short positions, so they are not a statement of what this fund owns.

Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy an interest in any fund or insurance policy. Interests in private funds are offered only to eligible investors, by the fund's own offering documents. Past performance, estimated or reported, does not predict future results. The calculators are illustrations built on assumptions you can change. To report an error, write to the editor.

Full legal name Sofinnova Bioequities Master Fund, Ltd.SEC private fund ID 805-6556194744Updated 15 November 2026
Private consultation →
Step 1 of 2

Tell us about yourself

Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.

✦Research assistant
✦PPLI.comResearch assistant
Explore PPLI questions and suitability factors
Ask a general question about PPLI, or explore the factors that affect suitability. Treat the answer as a starting point and check the linked sources.
Use the research with your own tax, legal and insurance advisers.
Preparing an answer
AI assistant. Educational information only. It does not determine eligibility or provide personal tax, legal, investment or insurance advice.